Natera stock targets more than $6 billion revenue by 2029
Published on 11/21/2026 at 11:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSNatera expands its growth roadmap
- Management presented Signatera as the central driver of the company's next growth phase.
- Reimbursement progress, clinical milestones and a CEO transition remain key execution factors.
- Signatera's average selling price stood at about 1,290 US dollars, with management targeting 1,450 US dollars by 2029.
Natera used its appearance at the Jefferies Global Healthcare Conference on November 18 to outline a broader growth roadmap. The company said revenue grew 42 percent year over year excluding true-ups, while full-year 2026 revenue guidance stood above 3 billion US dollars, according to a Reuters transcript published by Investing.com.
Signatera drives the plan
Signatera remains the main engine of the strategy. Management described an annual market opportunity of roughly 20 billion US dollars and said the test had reached about 1 billion US dollars of that opportunity so far.
The company cited an average selling price of about 1,290 US dollars and a goal of 1,450 US dollars by 2029. Higher reimbursement, additional MolDX coverage, Medicare Advantage compliance and broader commercial payer coverage are among the routes management identified for improving pricing.
Execution remains central
Management also pointed to the FIND-CRC colorectal cancer screening study, whose readout is expected in 2027 according to the conference discussion. Positive clinical results and reimbursement progress could expand the addressable market, while Signatera Genome is intended to improve assay sensitivity through broader sequencing and additional variant analysis.
The leadership transition adds another execution focus. Steve Bianchi is stepping down after eight years as chief executive, with Solomon Moshkevich set to take over. Management described the change as a continuity-focused handoff within a long-tenured team.
Natera stock traded at 251.75 euros on Lang & Schwarz at 11:30 CET on Saturday, November 21, 2026.
Natera company facts
- Company: Natera Inc.
- ISIN: US6323071042
- Ticker: NTRA
- Quote: 251.75 euros on Lang & Schwarz, November 21, 2026, 11:30 CET
Natera's shares remain part of the broader US market backdrop; see current market reports.
